#EQT #Stockholm #Switzerland #Galderma Group AG #share sale

EQT Successfully Finalizes Share Sale in Galderma Group AG

EQT, a well-known investment firm, has completed a significant transaction involving the sale of shares in Galderma Group AG. This important event marks a notable achievement for EQT and its investors, illustrating their ongoing commitment to effective portfolio management.

On June 2, 2025, EQT announced the successful placement of 19,031,811 shares in Galderma Group AG, a leading company in the field of dermatological treatments. The total gross proceeds from this sale amounted to approximately CHF 1.86 billion, a commendable figure that underscores the robust demand for Galderma's shares in the market. From this offering, EQT itself received roughly CHF 494 million.

The placement was executed through an accelerated bookbuilding process, enabling EQT to efficiently capitalize on favorable market conditions. Collaborating with esteemed financial institutions such as Goldman Sachs, Jefferies, Morgan Stanley, RBC, and UBS, EQT successfully coordinated the global placement, establishing a strategic pathway to optimize the transaction's execution.

This share placement is notable not just for its scale but also for the continued interest in Galderma Group AG. As a company recognized for its innovative contributions to dermatology, Galderma's reputation has attracted substantial investment interest, reflecting confidence in its future growth prospects.

The gross proceeds from the transaction will provide EQT and its investors with the necessary capital to explore new opportunities and enhance their existing portfolio. The successful placement serves as an indicator of the company’s strategic foresight in navigating the complex landscape of financial markets.

While EQT celebrates this accomplishment, it is important to note that this press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Galderma Group AG or its affiliates. Furthermore, it does not form a prospectus within the context of the Swiss Financial Services Act, nor does it represent an offer of securities for sale in the United States or other regions. In addition, there will be no public offering of any of the securities mentioned herein in the U.S., unless properly registered with the U.S. Securities and Exchange Commission or qualifying for an exemption from such registration.

EQT’s continued success in executing share placements highlights its proficiency in managing investments and identifying lucrative exit strategies. This move not only enhances EQT's balance sheet but also positions it to pursue new growth avenues while maintaining a keen focus on its overarching investment strategy.

The EQT team remains optimistic about the future and committed to delivering exceptional value to its stakeholders. In the coming months, it will be interesting to see how the proceeds from this sale are utilized as EQT continues to navigate through various market conditions and seek innovative paths for sustainable growth.

Conclusion

In summary, EQT's completion of the share sale in Galderma Group AG showcases not only its effective financial strategies but also the ongoing confidence in the dermatology sector. As EQT continues to thrive in the investment landscape, it sets a strong precedent for future transactions that could redefine opportunities within the market. Stakeholders can look forward to seeing how this transaction enhances EQT's strategic interests and growth trajectory in the months ahead.